Fennec Pharmaceuticals Files 2024 10-K

Ticker: FENC · Form: 10-K · Filed: Mar 26, 2025 · CIK: 1211583

Fennec Pharmaceuticals Inc. 10-K Filing Summary
FieldDetail
CompanyFennec Pharmaceuticals Inc. (FENC)
Form Type10-K
Filed DateMar 26, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-K, financials, pharmaceuticals

TL;DR

Fennec Pharma's 2024 10-K is in. Check financials for 2022-2024.

AI Summary

Fennec Pharmaceuticals Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, located in Research Triangle Park, NC, operates in the biological products sector. Key financial data points such as common stock and retained earnings for the years 2022, 2023, and 2024 are included in the filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Fennec Pharmaceuticals' financial performance and position as of December 31, 2024.

Risk Assessment

Risk Level: low — This is a standard annual financial filing with no immediate red flags.

Key Numbers

  • 27,527,000 — Common Stock (As of December 31, 2024)
  • 27,027,000 — Common Stock (As of December 31, 2023)
  • 11,800,000 — Additional Paid In Capital (As of December 31, 2024)
  • 19,500,000 — Retained Earnings (As of December 31, 2024)

Key Players & Entities

  • FENNEC PHARMACEUTICALS INC. (company) — Filer of the 10-K
  • RESEARCH TRIANGLE PARK, NC (location) — Business and mailing address
  • 2024-12-31 (date) — Fiscal year end
  • 20250326 (date) — Filing date

FAQ

What is Fennec Pharmaceuticals Inc.'s primary business sector?

Fennec Pharmaceuticals Inc. operates in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.

When is the fiscal year end for Fennec Pharmaceuticals Inc.?

The fiscal year end for Fennec Pharmaceuticals Inc. is December 31.

What is the filing date of this 10-K report?

This 10-K report was filed on March 26, 2025.

What are the key financial statement components reported for December 31, 2024?

Key financial statement components reported for December 31, 2024, include Common Stock ($27,527,000), Additional Paid In Capital ($11,800,000), and Retained Earnings ($19,500,000).

What was Fennec Pharmaceuticals Inc.'s previous company name?

Fennec Pharmaceuticals Inc. was formerly known as ADHEREX TECHNOLOGIES INC until December 23, 2002, and also as FENNEC PHARMACEUTICALS, INC. until September 3, 2014.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 26, 2025 regarding FENNEC PHARMACEUTICALS INC. (FENC).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.